Upcoming Second-Line NSCLC Treatments

David Heigener, MD, PhD, reports on the combination of checkpoint inhibition and PL1 inhibition, which produced the slowest tumor progression rate in an animal model compared to the components alone or a vehicle.

He discusses the available data and additional future therapies in NSCLC treatment, at the World Conference on Lung Cancer in Barcelona in September of 2019.

Video Source: Youtube
Video Content: Springer Healthcare IME

Next Up In NSCLC

Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo

Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo

New Combination Therapy Reaches Primary Endpoint in NSCLC Trial

New Combination Therapy Reaches Primary Endpoint in NSCLC Trial

NCCN Update on Systemic Therapies for Lung Cancer

NCCN Update on Systemic Therapies for Lung Cancer

Upcoming Second-Line NSCLC Treatments

Upcoming Second-Line NSCLC Treatments

Radiation Induces Systemic Immune Response in NSCLC

Radiation Induces Systemic Immune Response in NSCLC

Immunotherapy's Expanding Indications: Standard Shift

Immunotherapy's Expanding Indications: Standard Shift

Immunotherapy's Expanding Indications: ImmunoPlus

Immunotherapy's Expanding Indications: ImmunoPlus

Failure of First-line Cancer Treatment as a Result of Smoking

Failure of First-line Cancer Treatment as a Result of Smoking

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors

ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment

ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment

Investigational KRAS G12C Inhibitor Shows Positive Phase 2 Results in NSCLC

Investigational KRAS G12C Inhibitor Shows Positive Phase 2 Results in NSCLC

New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans

New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans

Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC

Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC

Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement

Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement

FDA Grants Breakthrough Device Designations for MRD Test

FDA Grants Breakthrough Device Designations for MRD Test

Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC

Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC

Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC

Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC

The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC

The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC

No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation

No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation

Guideline Update in Stage IV NSCLC with Driver Alterations

Guideline Update in Stage IV NSCLC with Driver Alterations

Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC

Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC

Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC

Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC

FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment

FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment

FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC

FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer

Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer

FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC

FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC

Nivolumab Loses Small Cell Lung Cancer Indication

Nivolumab Loses Small Cell Lung Cancer Indication

FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients

FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients

FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression

FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression

Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC

Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC

ESMO Updates Clinical Practice Guidelines for SCLC

ESMO Updates Clinical Practice Guidelines for SCLC

FDA Approves New Dosing for Durvalumab as NSCLC Treatment

FDA Approves New Dosing for Durvalumab as NSCLC Treatment

FDA Grants Priority Review for Fixed Dose Durvalumab

FDA Grants Priority Review for Fixed Dose Durvalumab

Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective

Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective

FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment

FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment

CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC

CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC

NSCLC Diagnostic Test Speed Improved by New Automated Algorithm

NSCLC Diagnostic Test Speed Improved by New Automated Algorithm

Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC

Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC

Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC

Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC

New Guidelines for Immunotherapy Use in Lung Cancer

New Guidelines for Immunotherapy Use in Lung Cancer

MD /alert Exclusives

Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC

Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC

Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer

Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer

Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC

Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC

No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation

No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation

Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC

Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC

The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC

The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC

Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC

Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC

ESMO Updates Clinical Practice Guidelines for SCLC

ESMO Updates Clinical Practice Guidelines for SCLC

New Guidelines for Immunotherapy Use in Lung Cancer

New Guidelines for Immunotherapy Use in Lung Cancer

FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment

FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment

Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC

Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC

Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC

Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC

FDA Grants Breakthrough Device Designations for MRD Test

FDA Grants Breakthrough Device Designations for MRD Test

CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC

CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression

FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression

Guideline Update in Stage IV NSCLC with Driver Alterations

Guideline Update in Stage IV NSCLC with Driver Alterations

Nivolumab Loses Small Cell Lung Cancer Indication

Nivolumab Loses Small Cell Lung Cancer Indication

FDA Approves New Dosing for Durvalumab as NSCLC Treatment

FDA Approves New Dosing for Durvalumab as NSCLC Treatment

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors

Investigational KRAS G12C Inhibitor Shows Positive Phase 2 Results in NSCLC

Investigational KRAS G12C Inhibitor Shows Positive Phase 2 Results in NSCLC

FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC

FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC

FDA Grants Priority Review for Fixed Dose Durvalumab

FDA Grants Priority Review for Fixed Dose Durvalumab

FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC

FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC

FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients

FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients

New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans

New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans

NSCLC Diagnostic Test Speed Improved by New Automated Algorithm

NSCLC Diagnostic Test Speed Improved by New Automated Algorithm

ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment

ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment

Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement

Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement

Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective

Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective

Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC

Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC

New Combination Therapy Reaches Primary Endpoint in NSCLC Trial

New Combination Therapy Reaches Primary Endpoint in NSCLC Trial

Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo

Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo

Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC

Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC

FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment

FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment

Breaking Research

Radiation after Immunotherapy Improves PFS in NSCLC

Radiation after Immunotherapy Improves PFS in NSCLC

Failure of First-line Cancer Treatment as a Result of Smoking

Failure of First-line Cancer Treatment as a Result of Smoking

Two New Targets Discovered for NSCLC Treatments

Two New Targets Discovered for NSCLC Treatments

Featured NSCLC Videos

Immunotherapy's Expanding Indications: ImmunoPlus

Immunotherapy's Expanding Indications: ImmunoPlus

Immunotherapy's Expanding Indications: Standard Shift

Immunotherapy's Expanding Indications: Standard Shift

Curated For You

Radiation Induces Systemic Immune Response in NSCLC

Radiation Induces Systemic Immune Response in NSCLC

NCCN Update on Systemic Therapies for Lung Cancer

NCCN Update on Systemic Therapies for Lung Cancer

Upcoming Second-Line NSCLC Treatments

Upcoming Second-Line NSCLC Treatments